Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 11 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards include non-statutory stock options for up to 161,300 shares of common stock at the August 19, 2026 closing price and restricted stock units (RSUs) for 51,200 shares.
The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the first anniversary of each employee’s start date and the balance vesting in 12 equal quarterly installments, subject to continued service. The RSUs are scheduled to vest in four equal annual installments over four years, also subject to continued service. The grants were made under Dyne’s 2024 Inducement Stock Incentive Plan and award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
The grants were made, but the covered shares are subject to vesting; options also require exercise, so any effect on existing common holders occurs only if the awards result in shares being issued.
Market Context
Insider data recorded Net Selling, adding ownership context to the 11-hire equity-award announcement...
Analysis
Insider data recorded Net Selling, adding ownership context to the 11-hire equity-award announcement. The platform also reports moderate short positioning, while the four-year vesting schedule is the relevant structural detail for ongoing context.
Key Figures
New hires:11 employeesStock options:161,300 sharesRestricted stock units:51,200 shares+5 more
Company priced 18,300,000 shares at $20.50 per share
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
DYN's recent news reactions were mostly positive, with four of five events showing gains; the prior inducement-grant event recorded the largest gain.
Key Terms
nasdaq listing rule 5635(c)(4), non-statutory stock options, restricted stock units
3 terms
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-statutory stock optionsfinancial
"The inducement equity awards consisted of non-statutory stock options"
Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.
restricted stock unitsfinancial
"and restricted stock units with respect to an aggregate of 51,200 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees.The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 161,300 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on August 19, 2026, and restricted stock units with respect to an aggregate of 51,200 shares of Dyne’s common stock.The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates.The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts: Investors Mia Tobias ir@dyne-tx.com 781-317-0353
What inducement equity grants did Dyne Therapeutics (DYN) announce on August 20, 2026?
Dyne Therapeutics announced inducement equity awards for 11 new employees, including options for 161,300 shares and RSUs for 51,200 shares. According to Dyne Therapeutics, these awards were granted under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
How many shares are covered by the new Dyne Therapeutics (DYN) inducement stock options and RSUs?
The inducement grants cover options to purchase up to 161,300 shares and RSUs for 51,200 shares of Dyne common stock. According to Dyne Therapeutics, the option exercise price equals the Nasdaq closing price on August 19, 2026, for its shares.
What are the vesting terms for the Dyne Therapeutics (DYN) inducement stock options granted in August 2026?
Dyne’s inducement stock options have a ten-year term and vest over four years. According to Dyne Therapeutics, 25% vests on the first anniversary of each employee’s start date, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service.
How do the restricted stock units (RSUs) granted by Dyne Therapeutics (DYN) vest for new employees?
The RSUs granted as inducement awards are scheduled to vest over four years from each employee’s start date. According to Dyne Therapeutics, vesting occurs in four equal annual installments, subject to the employee’s continued service through the applicable vesting dates.
Under which plan were the Dyne Therapeutics (DYN) August 2026 inducement awards granted?
The inducement awards were granted under Dyne’s 2024 Inducement Stock Incentive Plan and related award agreements. According to Dyne Therapeutics, these equity awards were structured to comply with Nasdaq Listing Rule 5635(c)(4) for inducement grants to new hires.
Why did Dyne Therapeutics (DYN) use Nasdaq Listing Rule 5635(c)(4) for these inducement grants?
Dyne used Nasdaq Listing Rule 5635(c)(4) because the equity awards were a material inducement to new employees accepting employment. According to Dyne Therapeutics, this rule allows specific inducement grants outside shareholder-approved plans, subject to disclosed terms and conditions.
